BioStock: Positive uTREAT-results in glioblastoma for Curasight

Biotech company Curasight recently revealed preclinical data demonstrating the effectiveness of uTREAT in treating glioblastoma. This discovery marks a significant step in the development of uTREAT as a new brain cancer therapeutics. BioStock contacted CEO Ulrich Krasilnikoff to learn more about what this milestone means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/06/positive-utreat-results-in-glioblastoma-for-curasight/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se